JW Pharmaceutical Corp (001065) — Cash Flow Reinvestment Rate
JW Pharmaceutical Corp (001065) has a Cash Flow Reinvestment Rate of 0.25x as of June 2026, reinvesting ₩10.79 Billion (capex ₩4.52 Billion plus investments ₩-6.27 Billion) from operating cash flow of ₩42.51 Billion. See JW Pharmaceutical Corp (001065) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
JW Pharmaceutical Corp Cash Flow Reinvestment Rate (2014–2025)
Historical reinvestment intensity for JW Pharmaceutical Corp across 11 annual periods. For the full cash flow conversion analysis, see 001065 cash generation efficiency.
Annual Cash Flow Reinvestment Rate for JW Pharmaceutical Corp (2014–2025)
Year-by-year capital reinvestment analysis for JW Pharmaceutical Corp. See JW Pharmaceutical Corp (001065) flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.73x | ₩70.18 Billion | ₩96.40 Billion | ₩36.12 Billion | ▼ -3.5% |
| 2024 | 0.75x | ₩59.86 Billion | ₩79.39 Billion | ₩28.14 Billion | ▼ -37.1% |
| 2023 | 1.20x | ₩104.49 Billion | ₩87.16 Billion | ₩40.71 Billion | ▲ +87.7% |
| 2022 | 0.64x | ₩36.26 Billion | ₩56.76 Billion | ₩9.92 Billion | ▲ +35.5% |
| 2021 | 0.47x | ₩8.55 Billion | ₩18.12 Billion | ₩7.47 Billion | ▼ -60.0% |
| 2020 | 1.18x | ₩74.34 Billion | ₩63.05 Billion | ₩12.39 Billion | ▲ +529.0% |
| 2019 | 0.19x | ₩10.41 Billion | ₩55.53 Billion | ₩9.28 Billion | ▼ -29.3% |
| 2018 | 0.27x | ₩13.82 Billion | ₩52.11 Billion | ₩8.64 Billion | ▲ +17.9% |
| 2017 | 0.22x | ₩7.52 Billion | ₩33.45 Billion | ₩7.50 Billion | ▼ -91.9% |
| 2016 | 2.79x | ₩18.79 Billion | ₩6.74 Billion | ₩10.02 Billion | ▲ +131.2% |
| 2014 | 1.21x | ₩8.78 Billion | ₩7.28 Billion | ₩6.93 Billion | — |